COMPANY

OVERVIEW

Company Name CureApp (CureApp, Inc.)
Head Office 103-0001 Kodenma-Cho YS building 4th floor
12-5, Nihonbashi Kodenma-Cho, Chuo-ku, Tokyo, Japan
US subsidiary CureApp North America, Inc.
440 N Wolfe Rd, Sunnyvale CA, 94085
Established July 31, 2014
Founder Kohta Satake, Shin Suzuki

HISTORY

July 2014
  • CureApp, Inc was established.
December 2014
  • Selected for "I-Challenge! (the ICT Innovation Creation Challenge Program)" sponsored by the Ministry of Internal Affairs and Communications.
February 2015
  • Procured approximately 30 million yen by raising capital through third-party allocation.
  • Started clinical research on applications for treating nicotine addiction at Keio University Hospital.
October 2015
  • Procured approximately 70 million yen by raising capital through third-party allocation.
  • Granted the The Ministry of Economy, Trade and Industry "Monodzukuri Grant".
November 2015
  • Made the decision to adopt NEDO "research and development type venture support".
February 2016
  • Achieved second-class medical device manufacturing and sales business status.
October 2016
  • The Department of Gastroenterology and the University of Tokyo Medical School Hospital and NASH (nonalcoholic steatohepatitis) Clinical research of therapeutic applications began.
  • Obtained an Information Security Management System (ISMS).
January 2017
  • Selected for the "HIYAKU Next Enterprise" Program sponsored by the Ministry of Economy, Trade and Industry (dispatched to Silicon Valley).
February 2017
  • Procured approximately 380 million yen by raising capital through third-party allocation.
April 2017
  • Launched the "ascure smoking cessation program" as the first series of a mobile health program for corporate users.
October 2017
  • Started clinical tests on applications for treating nicotine addiction.
February 2018
  • Procured approximately 1.5 billion yen by raising capital through third-party allocation.
March 2018
  • Acquired the "Privacymark (P mark)," provided by JIPDEC.
June 2018
  • Started clinical research on hypertension treatment applications at multiple institutions, including Jichi Medical University Hospital.
  • Selected for the "J-Startup" Program sponsored by the Ministry of Economy, Trade and Industry.
March 2019
  • Established CureApp North America, Inc.
May 2019
  • Announced the results of Japan's first "clinical test of an app" at the American Thoracic Society 2019 International Conference.
  • Announced the effectiveness of the treatment applications for nicotine addiction in smoking cessation outpatient clinics via Phase III clinical trials in Japan.
August 2019
  • Procured approximately 2.3 billion yen by raising capital through third-party allocation.
May 2020
  • The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan.
June 2020
  • CureApp Awarded as Technology Pioneer by World Economic Forum.
August 2020
  • CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups.
  • Asia’s First Prescription “Digital Therapeutic” Approved in Japan ; Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval.
Nobember 2020
  • Partnered with Daiichi Sankyo INC. to develop a Prescription Digital Therapeutic App for Breast Cancer
December 2020
  • CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
March 2021
  • Raised over 2.1 billion yen by through an allocation of newly issued common stock, reaching a cumulative of over 6.4 billion yen to date.
  • Our hypertension therapeutics app, has completed a Japanese Phase III multi-center randomized controlled trial. The research for the app was carried out in collaboration with a team led by Professor Kazuomi Kario at Jichi Medical University.
May 2021
  • Began clinical trial for digital therapeutics for alcoholism at Okayama City Hospital in Japan
July 2021
  • CureApp launches an online smoking cessation platform, ascureDr for Smoking Cessation, for health insurance associations, companies, and municipalities, which provides easier access to the therapeutic apps.
August 2021
  • Selected for the Tokyo Metropolitan Government Project to Build Next-Generation Wellness Solutions. (Content related to the development of a program to prevent serious diseases, specializing in hypertension prevention)
  • Presented the clinical trial results of a hypertension treatment app at ESC Congress 2021, and published the results in the European Heart Journal.
September 2021
  • CureApp was selected for the Tokyo Metropolitan Government’s Startup Promotion Project, PoC Ground Tokyo.
October 2021
  • CureApp’s alcoholism treatment project was selected for AMED’s Medical-Industrial Collaboration Innovation Promotion Project.
November 2021
  • Added a page about sustainability efforts.
  • Listed on Nikkei Trendy (a Japanese business newspaper) "2022 Hit Prediction Ranking".
  • "Online Non-smoking support by instructors" and "On-line non-smoking treatment by doctor" with "POC GROUND TOKYO" in the Tokyo Metropolitan Startup Supplementary Experiment Promotion Project.
December 2021
  • Partnered with a medical corporation Yumino to develop a chronic heart failure treatment app.
  • Won the Minister of Economy, Trade and Industry in the 21st JAPAN Venture Awards.
  • "2021 Japan Excellent Products and Service Award" Winner award.
April 2022
  • Received the Marketing authorization (Regulatory Approval) for the “Digital Therapeutic App for Hypertension”.
June 2022
  • Paper about cost-effectiveness of Digital Therapeutic App for Hypertension is published in Hypertension Research Journal.
August 2022
  • A license agreement with Sawai Group Holdings for the development and marketing of a DTx solution in the NASH field.
September 2022
  • Digital Therapeutic App for Hypertension: Introducing a New Form of App-based Prescription Treatment Reimbursed in Japan’s Public Healthcare Insurance System.
Norbember 2022
  • Partnered with Fukusima Medical University to develop a Prescription Digital Therapeutic App for Chronic Low Back Pain
December 2022
  • Clinical trial begins for the alcohol addiction treatment app.
January 2023
  • "ascure Smoking Cessation," a fully online smoking cessation program, reaches 300 corporate installations.
June 2023
  • Received Judging Committee's Special Award of Startup Award 2023 (NIPPON STARTUP AWARD)
September 2023
  • Selected for the GSAP (Global Startup Acceleration Program) hosted by Alchemist and JETRO
October 2023
  • Selected for the “J-Startup Impact” (startup development support program)sponsored by the Ministry of Internal Affairs and Communications.
  • “ascure smoking cessation program” adopted as Osaka City’s smoking cessation support program
  • Digital health program “ascure” is introduced to 350 corporate entities including Osaka City and other municipalities, corporate health insurance societies, and employers.
December 2023
  • "2023 Japan Excellent Products and Service Award" Nikkei Industry Newspaper Award.
February 2024
  • "The 5th IP BASE AWARD Startup Division” Encouragement Prize Winner.
  • Started clinical trial for Prescription digital Therapeutic App for NASH (Non-Alcoholic Steatohepatitis).
May 2024
  • Ranked in the” World's Best Digital Health Companies 2024” list